Navigation Links
DecisionView Unveils the Next Generation of Clinical Trial Software: StudyOptimizer 4.0

Web-based Software Significantly Improves Patient Recruitment Process

SAN FRANCISCO, Oct. 21 /PRNewswire/ -- DecisionView, Inc., the leading provider of software solutions to optimize clinical trial performance for life sciences companies, today announced the availability of StudyOptimizer 4.0, the latest version of its Web-based software solution. Designed to improve the patient recruitment process in clinical trials, the new StudyOptimizer 4.0 software provides significant, measurable business results.

"As clinical trials are becoming increasingly larger, more expensive and more complex, StudyOptimizer 4.0 provides additional functionality to help solve the challenges faced by enrollment planners and clinical operations worldwide," said Steve Andrade, CEO, DecisionView. "Our latest iteration significantly improves clinical trial performance and predictability, offering pharmaceutical companies with a tangible way to improve cost and efficiency."

Under development for more than a year, StudyOptimizer 4.0 represents a major milestone for DecisionView. The new product offers significant new features designed to improve user experience, performance, scalability and reliability.

"StudyOptimizer's advanced analytics and visualization combined with the wealth of research experience of our study managers, and a rejection of the 'ready, aim, fire' approach to clinical trial planning, has enabled GSK to double the frequency with which trials are completed on-time," said Alex Lancksweert, director of Business Performance Analytics at GlaxoSmithKline. "StudyOptimizer has enabled our teams to work in a more collaborative style to create robust plans grounded on empirically justified assumptions, and to streamline decision making by more effectively communicating trial progress to a dispersed study team and participating research sites."

Built atop a new and modern architecture, StudyOptimizer 4.0 includes new features such as:

-- New User Interface Framework. The new user interface is designed to streamline navigation and accelerate user adoption. A new task pane allows users to understand and execute the steps needed to complete a recruitment plan. Charts, legends, tables, columns and other UI elements can be easily hidden or resized to give users more control over the application look and feel. The new framework also includes a new caching mechanism that considerably improves response times when navigating throughout the application.

-- New Analytic Engine. StudyOptimizer 4.0 features OLAP technology that performs complex calculations and delivers analytic views into operational data. This new feature not only improves overall application performance, but also provides the foundation for StudyOptimizer's innovative visualizations of enrollment data.

-- New J2EE Application Server. A new, enterprise-class J2EE server -- built leveraging object-oriented design patterns -- delivers higher reliability, scalability, availability, and performance. It abstracts business logic from data storage and interfaces with the data warehouse and analytic engine to present information to the StudyOptimizer rich client.

-- Enhanced Administration. The StudyOptimizer Administration application provides an enhanced security model for defining access privileges and study access groups. User profiles now include new attributes, such as e-mail addresses and job titles. Integration with LDAP servers has been enhanced to import LDAP users in batch mode, either dynamically or at a scheduled time.

Due to its intrinsic service-oriented nature, this new architecture facilitates the development and release of new features in a more modular approach, allowing for more rapid and efficient innovation. The modular nature will also provide easier entry points for customers who will be able to license functionality incrementally according to their business needs.

About DecisionView

DecisionView develops innovative Web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView improves the visibility and predictability of clinical trial performance by automating critical clinical trials processes with integrated predictive analytics, simulation and scenario modeling capabilities that deliver proven business value, including faster cycle times and reducing clinical trials costs. Granite Ventures, Partech International and Aeris Capital are primary investors in the company.

For additional information, visit

SOURCE DecisionView, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference
2. ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services
3. USA-ONE Interactive Unveils Visioneer OneTouch Scanning into the Docuvation Content Management Solution
4. American Airlines Unveils Largest Aircraft Branded With Susan G. Komen for the Cures Streaming Pink Ribbon
5. Medco CEO Unveils Pragmatic Blueprint for Health Care Reform; Reducing Costs by Upwards of $1 Trillion
6. Florida Hospital Unveils New Details, Name for Childrens Hospital of the Future
7. UBC scientist unveils secret of newborns first words
8. Medical Records Institute Unveils Platform for Studying Cell Phone Applications in Healthcare
9. Johnson & Johnson Unveils Olympic Games Pavilion Featuring Authentic Qin Shi Huang Terracotta Warrior Exhibit
10. LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients
11. Video: Allen Institute for Brain Science Unveils Worlds First Genome-Wide Spinal Cord Atlas
Post Your Comments:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
Breaking Medicine Technology: